- Poster presentation
- Open Access
Use of albumin in spontaneous bacterial peritonitis is cost-effective
Critical Care volume 19, Article number: P353 (2015)
Assessing the cost-effectiveness of therapeutic interventions is increasingly crucial for health decision-making. Spontaneous bacterial peritonitis (SBP) is one of the major complications of liver cirrhosis. The use of albumin in conjunction with antibiotics has been shown to be effective through clinical trials .
A decision tree (TreeAge®) (Figure 1) was populated from published sources for clinical, cost and epidemiologic variables. The perspective taken was that of the US payer. The robustness of the model was checked using one-way and probabilistic sensitivity analyses. The clinical course was followed for 3 months or until death. Total medical costs and quality-adjusted life years (QALYs)  were calculated.
The use of albumin in the treatment of SPB is cost-effective.
Poca M, et al: Clin Gastroenterol Hepatol. 2012, 10: 309-15. 10.1016/j.cgh.2011.11.012.
Wells CD, et al: Dig Dis Sci. 2004, 49: 453-8.
About this article
Cite this article
Farrugia, A., Bansal, M. & Caraceni, P. Use of albumin in spontaneous bacterial peritonitis is cost-effective. Crit Care 19, P353 (2015). https://doi.org/10.1186/cc14433
- Public Health
- Clinical Trial
- Sensitivity Analysis
- Decision Tree